These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29923986)

  • 21. Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study.
    Voors AA; Dahlke M; Meyer S; Stepinska J; Gottlieb SS; Jones A; Zhang Y; Laurent D; Slart RH; Navis GJ
    Circ Heart Fail; 2014 Nov; 7(6):994-1002. PubMed ID: 25286914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU.
    Maggioni AP; López-Sendón J; Nielsen OW; Hallén J; Aalamian-Mattheis M; Wang Y; Ertl G
    Eur J Heart Fail; 2019 Mar; 21(3):322-333. PubMed ID: 30604559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF.
    Metra M; Ponikowski P; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Hua TA; Severin T; Unemori E; Voors AA; Teerlink JR
    Eur Heart J; 2013 Oct; 34(40):3128-36. PubMed ID: 23999454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF.
    Liu LC; Voors AA; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Chen Y; Greenberg BH; Ponikowski P; Pang PS; Prescott MF; Hua TA; Severin TM; Metra M
    Clin Res Cardiol; 2016 Sep; 105(9):727-37. PubMed ID: 27017514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure.
    Sato N; Takahashi W; Hirayama A; Ajioka M; Takahashi N; Okishige K; Wang X; Maki A; Maruyama H; Ebinger U; Yamaguchi M; Pang Y; Matsumoto H; Kawana M
    Circ J; 2015; 79(6):1237-47. PubMed ID: 25912697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2.
    Loungani RS; Teerlink JR; Metra M; Allen LA; Butler J; Carson PE; Chen CW; Cotter G; Davison BA; Eapen ZJ; Filippatos GS; Gimpelewicz C; Greenberg B; Holbro T; Januzzi JL; Lanfear DE; Pang PS; Piña IL; Ponikowski P; Miller AB; Voors AA; Felker GM
    JACC Heart Fail; 2020 Dec; 8(12):999-1008. PubMed ID: 33189635
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serelaxin in clinical development: past, present and future.
    Unemori E
    Br J Pharmacol; 2017 May; 174(10):921-932. PubMed ID: 28009437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial.
    Sato N; Lam CS; Teerlink JR; Greenberg BH; Tsutsui H; Oh BH; Zhang J; Lefkowitz M; Hua TA; Holbro T; Marshood M; Wang XL; Ge J
    J Card Fail; 2017 Jan; 23(1):63-71. PubMed ID: 27825893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions.
    Díez J
    Am J Cardiovasc Drugs; 2014 Aug; 14(4):275-85. PubMed ID: 24590581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant human relaxin versus placebo for cervical ripening: a double-blind randomised trial in pregnant women scheduled for induction of labour.
    Weiss G; Teichman S; Stewart D; Nader D; Wood S; Breining P; Unemori E
    BMC Pregnancy Childbirth; 2016 Sep; 16(1):260. PubMed ID: 27596360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.
    Filippatos G; Farmakis D; Metra M; Cotter G; Davison BA; Felker GM; Greenberg BH; Hua TA; Pang PS; Ponikowski P; Qian M; Severin TA; Voors AA; Teerlink JR
    Clin Res Cardiol; 2017 Jun; 106(6):444-456. PubMed ID: 28150186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection.
    Díez J; Ruilope LM
    Eur Heart J Cardiovasc Pharmacother; 2016 Apr; 2(2):119-30. PubMed ID: 27418970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serelaxin (recombinant human relaxin-2) treatment affects the endogenous synthesis of long chain poly-unsaturated fatty acids and induces substantial alterations of lipidome and metabolome profiles in rat cardiac tissue.
    Aragón-Herrera A; Feijóo-Bandín S; Abella V; Álvarez L; Roselló-Lletí E; Portolés M; Tarazón E; Bigazzi M; Bani D; Gualillo O; González-Juanatey JR; Lago F
    Pharmacol Res; 2019 Jun; 144():51-65. PubMed ID: 30954631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serelaxin and acute heart failure.
    Tietjens J; Teerlink JR
    Heart; 2016 Jan; 102(2):95-9. PubMed ID: 26603680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations.
    Dahlke M; Ng D; Yamaguchi M; Machineni S; Berger S; Canadi J; Rajman I; Lloyd P; Pang Y
    J Clin Pharmacol; 2015 Apr; 55(4):415-22. PubMed ID: 25408331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1.
    Wilhelmi T; Xu X; Tan X; Hulshoff MS; Maamari S; Sossalla S; Zeisberg M; Zeisberg EM
    Theranostics; 2020; 10(9):3905-3924. PubMed ID: 32226528
    [No Abstract]   [Full Text] [Related]  

  • 37. Serelaxin (recombinant human relaxin-2) prevents high glucose-induced endothelial dysfunction by ameliorating prostacyclin production in the mouse aorta.
    Ng HH; Leo CH; Parry LJ
    Pharmacol Res; 2016 May; 107():220-228. PubMed ID: 26993102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serelaxin for infant heart failure in congenital dilated cardiomyopathy.
    Myers PO; Bordessoule A; Tissot C
    Cardiol Young; 2018 May; 28(5):734-736. PubMed ID: 29332614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increase of cortical cerebral blood flow and further cerebral microcirculatory effects of Serelaxin in a sheep model.
    Bischoff SJ; Schmidt M; Lehmann T; Irintchev A; Schubert H; Jung C; Schwab M; Huber O; Matziolis G; Schiffner R
    Am J Physiol Heart Circ Physiol; 2016 Sep; 311(3):H613-20. PubMed ID: 27402664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serelaxin: new investigational treatment in acute heart failure.
    Said S; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2013 Sep; 11(3):243-8. PubMed ID: 24289727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.